-
1 Comment
Zhejiang Shouxiangu Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 1.0% below its 200 day moving average.
From a valuation standpoint, the stock is 12.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd's total revenue sank by 22.3% to $158M since the same quarter in the previous year.
Its net income has dropped by 63.1% to $25M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.7% to $60M since the same quarter in the previous year.
Based on the above factors, Zhejiang Shouxiangu Pharmaceutical Co., Ltd gets an overall score of 1/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| Sector | Healthcare |
| ISIN | CNE100002XJ4 |
| Industry | Biotechnology |
| Target Price | 31.4 |
|---|---|
| PE Ratio | 22.16 |
| Beta | 0.42 |
| Market Cap | 4B |
| Dividend Yield | None |
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale and ganoderma lucidum extract, dendrobium officinale granules, saffron extract, crocus sativus, and other health products. Zhejiang Shouxiangu Pharmaceutical Co., Ltd. was founded in 1997 and is based in Jinhua, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603896.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
